Hair Loss Treatments - Hair Loss Solutions from NetWideSales

Health: Men's Health

Lepidium Meyenii (Maca) natures viagra Maca reduced prostate size Maca use in erectile dysfunction

Health: Women's Health

Menopause Help Lepidium Meyenii Maca Root

Men's Hair Loss

Hair loss Information Understanding hair loss in men Folligen Products with CPs Tricomin Products with CPs Nizoral Shampoo Hair Max LaserComb®

Women's Hair Loss

Understanding hair loss in Women Minoxidil for Women Folligen Products with CPs Tricomin Products with CPs Nizoral Shampoo for thinning hair HairMax LaserComb®

FDA Approved Treatments

Read about FDA approved hair growth products
The HairMax LaserComb® Minoxidil/Rogaine®

Copper Peptides & Hair Growth

Copper Peptides & Hair Growth More on Copper Peptides Folligen Prodcuts with CPs Tricomin Products with CPs Nizoral Shampoo

GHK-CU Analogs & Hair Growth

GHK-CU Analogs and stimulation of hair growth

Testosterone & Hair Growth

Testosterone and hair growth Testosterone and DHT

Clinical & Scientific Studies

Stimulation of hair growth with copper peptides HairMax LaserComb® clinical studies Ketoconazole Chronic Use Ketoconazole Comparison Ketoconazole Efficacy

Hair Growth Stimulant Store

Visit our hair growth stimulant store to view and purchase products

HairMax LaserComb® Pro

HairMax LaserComb® Advanced 7

Hair Loss: HairMax Laser Comb Clinical Studies

Since 2001, Lexington International, LLC has conducted seven clinical studies with 460 subjects.

The key clinical study on the HairMax has been published in peer review journal.
Results of study used support HairMax LaserComb® FDA 510(k) submission
Clinical studies have shown that HairMax treated hair loss and promoted hair growth in 93% of users.
Lexington International, LLC reports that no serious side effects have been reported from treatment with the HairMax.

Since 2001, there have been seven clinical studies conducted on the HairMax LaserComb®. The most recent studies were conducted in 2010, with two of the studiesconducted on males and two conducted in females.

Clinical Results

Results of the clinical studies showed that subjects in the HairMax LaserComb® laser hair loss treatment group had:

Significantly greater increase in mean terminal hair count than subjects in the control group.
Significantly better subjective assessments of thickness and fullness of hair than subjects in the control group.
No subject experienced a serious adverse event from the laser hair loss treatment.
Adverse event profiles were similar between the HairMax and control groups.

The HairMax LaserComb®

Users of the HairMax LaserComb® laser hair growth treatment* received some or all of the following subjective benefits:

A substantial decrease in hair fallout.
Some users experienced an initial increase in telogen fallout after starting treatment, but after this period, new anagen growth was observed.
Increased speed of hair growth.
More manageability of the hair.
Overall better quality and condition of hair.

HairMax

Substantial increase in hair density. Overall improvement of hair quality

HairMax

Filling in of hairline. Substantial increase in hair density.
Overall improvement of hair quality.
The photos shown above are of actual HairMax LaserComb® users, but are not intended to represent results everyone who uses the device will necessarily experience. Qualified subjects had global images recorded at each visit using a stereotactic device.

Non-Vellus Hair Density Macro Images

At baseline, a circle approximately 1 inch in diameter, positioned in the transition zone of the scalp, was identified as the site for hair clipping and tattooing. Within this site was the target area for the hair density evaluation during the laser hair growth treatment. Subjects were evaluated at baseline, week 8, week 16 and week 26. Digital images captured by FUJI S2 were taken of the target site within the clipped area following the site preparation. A 19 inch monitor was used for blinded evaluation.
The image below corresponds with the un-retouched Macro images shown and demonstrate a 20% increase in hair growth density.

HairMax

Actual clinical study photo above shows 29 hair/cm increase after 26 weeks of laser hair growth treatment.

Study Objectives

promotion of hair growth through changes in hair count
cessation of hair loss
overall scalp health
safety

Study Design

All studies were designed as a multi-centered, double- blinded, randomized control-device trials conducted at eight sites in the United States. Subjects were instructed to use the laser hair growth treatment device three times per week on non-consecutive days, 10-15 minutes per treatment for a total of 26 weeks. Hair density measurements were performed at baseline immediately prior to randomization and again at 16 and 26 weeks. Additional clinical visits were scheduled to monitor the laser hair loss treatment progress and overall hair growth.

Subject Population and Demographics

The study population included males and females between the ages of 25 and 60 years with a diagnosis of Androgenetic Alopecia who had been experiencing active hair loss within the last 12 months. The inclusion criteria for males required a Norwood- Hamilton classification of IIa to V and Fitzpatrick skin types I to IV. The inclusion criteria for females required a Ludwig (Savin) classification of I-4, II-1, II-2, or frontal. All subjects were randomized for laser hair loss treatment analysis. A biostatistician calculated the study to be of a proper size to gauge statistically significant results of hair growth and hair density.

HairMax

Lexington limited the skin types for the subjects in the studies to Fitzpatrick I to IV to facilitate the hair counting process. It is difficult to count dark hairs on dark skin and therefore the darker Fitzpatrick skin types (V and VI) were not included in the study.

Methods

After diagnosing the scalp for Androgenetic Alopecia and exclusion of other dermatological conditions, subjects were randomized with either our active laser hair loss treatment device, or sham device. Subjects were then photographed for global evaluation and the target site of the scalp was identified and tattooed for baseline density. Subjects were then provided a device without usage instructions from the investigator per the protocol for OTC use. Subjects returned to the clinic at 8 and 16 weeks with a final visit at week 26 for clinical evaluation of hair counts and hair growth.
The results of the key clinical study performed with the HairMax LaserComb which led to FDA clearance to market was published in the May 2009 Issue of Clinical Drug Investigation. The article entitled, HairMax LaserComb® Phototherapy Device in the Treatment of Male Androgenetic Alopecia, is indexed as Clin Drug Invest 2009: 29 (5): 283-292 in most of the biomedical databases such as MEDLINE, EMBASE/Excerpta Medica, etc.

Please click here to read an abstract of this study

*The HairMax Advanced 7, Premium, Lux 9, and the Professional 12 models are indicated to treat Androgenetic Alopecia, and promote hair growth in males who have Norwood Hamilton Classifications of IIa to V and in females who have Ludwig (Savin) I-4, II-1, II-2, or frontal patterns of hair loss and who both have Fitzpatrick Skin Types I to IV.